The message that Ainnova's CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and ...

The message that Ainnova’s CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and ...

There’s room on the market for new TAVI valves as long as they can compete with the best in practice, a researcher says.

The neobank was blasted for "violations and shortcomings in the monitoring of business relationships and [transactions]" by ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Medtronic has reported late-breaking data from the Evolut Low Risk Trial’s five-year outcomes of the Evolut TAVR system.

Medtronic Evolut TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients: Galway, Ireland Tuesday, April 1 ...

On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. In the trial, TAVR, which assists patients ...

Medtronic (NYSE:MDT) recently saw a substantial price movement, climbing 10% over the last quarter. This period was marked by the release of promising five-year data from the Evolut Low Risk Trial, ...